If you read this blog with any regularity, you know I try to keep my topics educational. However, sometimes something new and interesting on the horizon is worthy of its own announcement, if only to determine if anyone else is excited about the potential as we are. In fact, more than ever, we would love to have feedback from you on the potential usefulness of this new test.
We love staying in the know. Now we blog about it. Keep up to date on company news and promotions. Enjoy educational seminars and stay informed with industry related news atricles, trends and compliance.
If you’ve watched our “Understanding the Limitations of Drug Testing” webinar or have had conversations with me about that subject, you’ve heard me talk about substances that many people expect to be detected on the tests they are using, but actually are not. An excellent example of this that we are all hopefully familiar with is Fentanyl.
The state of designer opioids is an ever changing landscape. When it comes to powerful street drugs such as designer opioids it is important to understand what is being produced and what to look out for. Chief Product Officer takes a deep dive into understanding current trends of designer opioids.
Today’s subject was sparked from a conversation that our sales consultants have fairly regularly. Usually this comes up in the context of us pressing to find out why a facility is using the specific tests that they are using. The answer we get more than any other is some variant of, “it’s just the way we’ve always done it.” If you’ve had any conversations with our sales team, you know they won’t simply let that answer stand alone. It is always our mission to understand the needs of each facility we work with, but sometimes this can entail explaining why some of the thought processes behind those needs might be misguided, outdated, or missing crucial bits of information.
Adulteration is an issue that most have encountered at one time or another in drugs of abuse management programs. Patients, or donors, sometimes go to great lengths to adulterate a specimen in an attempt to avoid a positive test result. In this video, Chief Product Officer, Eric Malis, discusses the importance of using and reading adulteration test strips correctly along with a hands on demonstration.
Something you may have noticed while browsing our product catalogs and/or listings is that some of the tests have a designation of “CLIA Waived”, while others are designated as “FUO”. What do these two designations refer to, and how does it affect you? Let us look a little deeper and find out.
In the latest NTS-U Webinar, join Chief Product Office, Eric Malis in discussing drugs of abuse commonly found at gas stations, convenience stores, and smoke shops; most of which are in legal gray areas.
Chief Product Officer, Eric Malis, demonstrates how to perform a surface residue test using one of our Dip Card test devices. Watch the full video to to get a step-by-step breakdown.
If you read the instructions that are included in each box of tests (stop laughing, some people have!) then you have seen the recommendation that “positive and negative controls be tested as good laboratory practice to confirm the test procedure and to verify proper test performance”. Every instant test does have built-in procedural controls
Know your substances! This on going series covers everything you should and need to know about the substances you’re testing for. Being well informed is one of the best ways to stay ahead of the curve. This episode will cover everything you need to know about Cocaine
Subscribe for More Great Articles!
Get up to date news directly to your virtual door. Make sure you subscribe to receive a personalized newsletter specifically tailored to you and your facilities interests and needs.